Study #2021-1176
A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and with checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
SD-101, anti-PD-1
Description
This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Pancreatic Adenocarcinoma
Study phase:
Phase I
Physician name:
Dan Zhao
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-558-2027
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.